Can you still fill a compounded semaglutide prescription with B12?

Short answer: No, not automatically. Adding vitamin B12 to a compounded semaglutide prescription does not by itself keep that product available under FDA policy, and getting the prescription through telehealth does not override federal compounding rules.

Three recent FDA actions are driving the confusion. On March 3, 2026, FDA said it sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products. On April 1, 2026, FDA clarified how it views compounded copies of commercially available GLP-1 drugs as national supply stabilizes. And on April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Taken together, those actions mean refill access now depends on the exact prescription, the compounding pathway, the pharmacy involved, and whether there is a documented patient-specific reason for compounding.

Why adding B12 does not create an automatic exception

FDA’s April 1 clarification directly addressed the idea that semaglutide plus another ingredient is automatically different enough to remain available. The agency said a compounded product that combines semaglutide with another active ingredient, including vitamin B12, may still be considered essentially a copy of a commercially available drug product.

In plain language, FDA is saying that adding B12 is not a free pass. If the compounded product uses the same route of administration, such as an injection, and the strengths are the same, similar, or easily substitutable, FDA may still view it as a copy unless the prescriber has documented a significant difference for a specific patient.

That patient-specific documentation is important. Under the traditional 503A compounding pathway, the prescription must be for an identified individual patient, and the prescriber must explain why the compounded version is meaningfully different for that person. Without that rationale, a semaglutide-plus-B12 formula may still face the same federal limits as other compounded copies.

Telehealth can prescribe, but it cannot override compounding rules

A telehealth visit can still be a legitimate medical visit, and a legitimate prescription still matters. But telehealth marketing does not change the legal rules for compounding.

FDA’s March 3 warning-letter announcement said the agency targeted telehealth companies that made false or misleading claims about compounded GLP-1 products. According to FDA, some companies implied their compounded products were the same as FDA-approved drugs or made it unclear who was actually making the medication. That matters because the website selling the drug may not be the pharmacy that compounds it.

So if you are using telehealth, the key question is not simply whether a company offers semaglutide with B12. Better questions are: Who is prescribing it? Which pharmacy is filling it? Is that pharmacy state licensed? And what is the documented reason a compounded version is needed instead of an FDA-approved product?

What changed on April 30

FDA’s April 30, 2026 action is a proposal, not a final rule. It focuses mainly on 503B outsourcing facilities, which are larger compounders that operate under a different part of federal law and can supply hospitals, clinics, and other buyers. FDA said it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list because it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances. The public comment deadline is June 29, 2026.

For patients, that does not mean every compounded prescription becomes illegal overnight. But it is another sign that the pathway for routine compounded GLP-1 access is narrowing, especially for products made from bulk substances at the outsourcing-facility level.

Why this is happening now

FDA’s April 1 clarification came as national GLP-1 supply conditions changed and the agency signaled that routine copycat compounding should not continue just because demand remains high. That matters because federal compounding rules are generally tighter when approved products are commercially available and a drug is no longer being treated as shortage-driven for compounding purposes.

During the shortage period, demand helped drive a rapid rise in compounded GLP-1 sales, including heavy online marketing. A 2025 JAMA Health Forum analysis described the growth of the compounded GLP-1 market and the policy and safety concerns that came with it. The American Diabetes Association has also recommended against non-FDA-approved compounded incretin products because of uncertainty about their content, safety, quality, and effectiveness.

Safety issues patients should not ignore

FDA says compounded GLP-1 products are not FDA-approved. That means the agency does not review them for safety, effectiveness, or quality before they are marketed.

FDA has also warned about several specific risks:

Dosing errors: FDA says it has received reports of dosing mistakes with compounded injectable semaglutide, including some that required hospitalization. Problems have included patients measuring the wrong dose and clinicians or pharmacies using dosing schedules that do not match approved labels.
Fraudulent labels: FDA says some products marketed as compounded semaglutide or tirzepatide have carried false label information, including pharmacies that do not exist or licensed pharmacies that did not actually make the product.
Illegal online sales: FDA warns that illegally marketed semaglutide products sold online may be counterfeit or may contain too little, too much, or none of the active ingredient.
Warm shipments: FDA says some compounded GLP-1 injections have arrived warm or without adequate cold packs. Improper storage can affect product quality.
Semaglutide salts: FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved drugs, and the agency says it is not aware of a lawful basis for using those salt forms in compounding.

If a dose is unclear, the label looks odd, or the medicine arrives warm, do not guess. Contact the prescriber and the dispensing pharmacy right away to verify what you received and how it should be used. If someone may have taken the wrong dose and is having severe symptoms, seek urgent medical care.

What to ask before your next refill

If you currently receive compounded semaglutide, especially a semaglutide-plus-B12 product, it is reasonable to ask:

Who exactly is prescribing this medication, and is the prescription written for me as an individual patient?
Which pharmacy or outsourcing facility is filling it?
What are the exact ingredients and strengths on the label?
Why is a compounded version needed instead of an FDA-approved product?
Has the prescriber documented a significant difference for me specifically?
How should I measure the dose, and what syringe or device should I use?
How should it be stored, and what should I do if it arrives warm?

Those questions can help you sort out whether your refill is likely to continue, whether the product is being presented accurately, and whether you are being asked to use something FDA has specifically warned about.

What remains uncertain

There is still no one-size-fits-all answer for every patient in the United States. FDA’s April 30 proposal is not final. Refill access may vary depending on whether the product is being made under the 503A or 503B pathway, how the prescription is written, what ingredients are used, and whether the prescriber has documented a real clinical difference for an identified patient.

Patients may also continue to see differences by pharmacy, prescriber, insurer, and local supply. A telehealth company may advertise availability, while a particular pharmacy may decide it cannot legally or appropriately keep filling the product the same way.

The bottom line

After FDA’s April 2026 actions, patients should not assume that semaglutide with B12 remains available just because B12 was added, and they should not assume that a telehealth prescription changes the rules. FDA has signaled the opposite: semaglutide-plus-B12 can still be treated as an essentially copied product, and telehealth marketing does not override federal compounding limits.

If you depend on a compounded refill, check the details before you run out. Ask your prescriber and pharmacy why the compounded product is being used, what exactly is in it, and whether the prescription still fits current FDA policy. Do not stop, switch, or stretch doses on your own, but do make sure you have clear answers before the next refill date.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.